I guarantee you this news will make your professional life a whole lot easier and even more gratifying.
All over the world, vascular access specialists are now using ultrasound to help insert peripheral IVs (PIVs). Because of this, central line insertions are often avoided and existing central lines are able to be discontinued. That’s the good news.
The bad news is: the median dwell time of ultrasound guided PIVs is 26 hours, and their failure rate is nearly 50%. Ultrasound-guided PIVs just cannot last, they are too short and made of the wrong material (i.e. polyurethane).
Fortunately, Access Scientific has the solution—POWERWAND™ EDC: The first power-injectable, non-trimmable 6cm extended-dwell, 3Fr catheter, specifically designed for ultrasound-guided peripheral IV access. Like all POWERWANDs, the EDC is made of ChronoFlex™C and inserted using either the XL method (easiest) or the accelerated Seldinger technique (fastest).
Does it perform? Preliminary data from a prestigious urban hospital—currently in the process of publishing these remarkable results—revealed the POWERWAND™ EDC average dwell time of 11.2 days. That’s longer than the vast majority of midlines! And, the POWERWAND™ EDC resulted in a 39.1% reduction of central line usage. No other peripheral IV in the world can boast such extraordinary results.
Imagine not having to go back again and again to the same patient to start and restart an ultrasound-guided PIV. Imagine not having to ultimately start a PICC or CVC and risk a CLABSI on that poor patient. Imagine the patient and family sincerely offering you their thanks.
There is a new and better tool in your toolbox—the revolutionary 6cm, 3Fr POWERWAND™ EDC. I’m sure if you try it, you’ll quickly realize it is by far the best peripheral vascular access device ever made.
Steve Bierman MD
Customers often ask, Why does the POWERWAND™ have so many fewer complications than the other midlines and extended-dwell catheters we have tried? Flip that over and it sounds like: Why do other non-POWERWAND midlines have so many more complications (DVTs, leaking, phlebitis, etc.) than POWERWAND midlines?
The answer is really quite simple: Cut catheters appear to cause irritation to the vessel lining (i.e., the intima), which in turn causes complications. Watch this video which depicts the dangers of cut catheters quite well.
The POWERWAND is not a cut catheter; its tip is thermoformed into an atraumatic ZERO-EDGE™ transition. Beyond that, the POWERWAND guidewire has a soft, plastic domed tip. Atraumatic POWERWAND insertion leads to superior clinical outcomes.
But there is more. The other midlines are all made of polyurethane or a polyurethane blend. Those polyurethane midlines with published outcome data all have higher bloodstream infection rates than POWERWAND. Why? Because the POWERWAND is not polyurethane. It is made of a remarkable new polymer called ChronoFlex C®, which before becoming a POWERWAND, goes through our proprietary manufacturing process. The result: Over 20,000 catheter-days of peer-reviewed, published studies, from 5 different investigators and 6 different institutions, with ZERO bloodstream infections.
Atraumatic insertion + Thermoformed ChronoFlex C = The undisputed best-in-class, POWERWAND midline and extended-dwell catheter. There is method to the POWERWAND magic.
Our hearts go out to all the children whose childhoods are interrupted by hospitalization. Thankfully, there is a new and simple way to lessen their suffering—a unique vascular access device that finally offers hospitalized children the true potential for a ONE-STICK hospitalization. That wonderful addition to our vascular access toolbox is the 3Fr Pediatric POWERWAND™.
Children’s wards and Children’s Hospitals all over the country are celebrating the advent of this new, all-purpose Pediatric POWERWAND for its extraordinary first-attempt success rate, superb blood-drawability, extended dwell times (up to 29 days) and minimal complications. As an accomplished pediatric vascular specialist in the Midwest recently said, “It’s so nice to have mothers actually squeezing our hands and thanking us. One told me the POWERWAND prevented her child from getting between 40-50 needlesticks.”
If your facility is a participant in the Children’s Hospitals Solutions for Patient Safety, you’ll be especially happy to learn that the Pediatric POWERWAND addresses 4+1 of the SPS Focus Goals. Used in conjunction with the Pediatric ZPad™ securement device and catheter cushion (which comes in the POWERWAND Pediatric kit, along with several other special accessories), the Pediatric POWERWAND is designed to reduce: (1) CLABSI, (2) Venous Thromboembolism, (3) PIVIEs (infiltrations and extravasations), (4) pressure injuries–PLUS (5) medical adhesive-related skin injuries.
The world of Pediatric vascular access just changed dramatically for the better. The Pediatric POWERWAND—giving hospitalized children their first true shot at a ONE-STICK hospitalization.
I am confident this new POWERWAND product will add greatly to the daily gratification of your important work.
Steve Bierman, MD
Definitive proof has finally arrived. PICCs are no longer required to deliver long-term or short-term vancomycin (4mg/ml). Over 1000 patients, representing over 8000 catheter-days, are reported in this month’s JAVA to have had no DVTs and no bloodstream infections and minimal phlebitis (0.6%) during intravenous vancomycin administration through the POWERWAND midline. (Full article)
What does this groundbreaking study mean for you and your institution?
In most hospitals, vancomycin administration is an indication for about 20% of PICCs. This new POWERWAND study demonstrates that these patients no longer need PICCs, which means you can reduce your central line days by roughly 20%. Instead of a PICC, a 4Fr or 5Fr POWERWAND placed in the deep vessels of the upper arm will get the job done safer and more cost-efficiently. In fact, placing a POWERWAND is usually at least $90.00 less expensive than placing a PICC.
Remember, only the POWERWAND midline has over 20,000 catheter days of published data attesting to zero bloodstream infections and the lowest complication rates of any vascular access device ever studied. (refs) Couple this with the news of safe vancomycin administration (over 5 years, in over 1000 patients) and you really have compelling reasons to support your POWERWAND use.
It’s a pleasure to share this information with you, because it means that everyone—patients and providers—gets to share the benefits POWERWAND use. Thank you for your continued, evidence-based support.
Steve Bierman, MD
Chief Medical Officer